Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results from the Randomized CREDENCE Trial.
CONCLUSIONS: Canagliflozin significantly reduced major cardiovascular events, as well as kidney failure, in patients with type 2 diabetes and chronic kidney disease, including in participants who did not have prior cardiovascular disease.
CLINICAL TRIAL REGISTRATION: URL: https://ClinicalTrials.gov Unique identifier: NCT02065791.
PMID: 31291786 [PubMed - as supplied by publisher]
Source: Circulation - Category: Cardiology Authors: Mahaffey KW, Jardine MJ, Bompoint S, Cannon CP, Neal B, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Capuano G, de Zeeuw D, Greene T, Levin A, Pollock C, Sun T, Wheeler DC, Yavin Y, Zhang H, Zinman B, Rosenthal N, Brenner BM, Perkov Tags: Circulation Source Type: research
More News: Canagliflozin | Cardiology | Cardiovascular | Chronic Kidney Disease | Clinical Trials | Diabetes | Diabetes Type 2 | Endocrinology | Heart | Heart Attack | Heart Failure | Invokana | Stroke | Study | Urology & Nephrology